Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists
A dangerous viral disease COVID-19, caused by a new RNA coronavirus SARS-COV-2, has been actively spreading in the world since December 2019. The main manifestations of this disease are bilateral pneumonia, often accompanied by the development of acute respiratory syndrome and respiratory failure. P...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2022-03-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12873 |
| _version_ | 1797255124514504704 |
|---|---|
| author | I. I. Dedov N. G. Mokrysheva M. V. Shestakova T. V. Nikonova A. Yu. Mayorov G. R. Galstyan M. Sh. Shamhalova V. O. Barysheva A. S. Ametov M. B. Antsiferov A. Yu. Babenko T. P. Bardymova F. V. Valeeva A. A. Vachugova E. N. Grineva T. Yu. Demidova T. P. Kiseleva M. A. Kunicyna T. N. Markova A. M. Mkrtumyan N. A. Petunina L. A. Ruyatkina V. V. Saluhov L. A. Suplotova E. L. Hadarceva Yu. Sh. Halimov |
| author_facet | I. I. Dedov N. G. Mokrysheva M. V. Shestakova T. V. Nikonova A. Yu. Mayorov G. R. Galstyan M. Sh. Shamhalova V. O. Barysheva A. S. Ametov M. B. Antsiferov A. Yu. Babenko T. P. Bardymova F. V. Valeeva A. A. Vachugova E. N. Grineva T. Yu. Demidova T. P. Kiseleva M. A. Kunicyna T. N. Markova A. M. Mkrtumyan N. A. Petunina L. A. Ruyatkina V. V. Saluhov L. A. Suplotova E. L. Hadarceva Yu. Sh. Halimov |
| author_sort | I. I. Dedov |
| collection | DOAJ |
| description | A dangerous viral disease COVID-19, caused by a new RNA coronavirus SARS-COV-2, has been actively spreading in the world since December 2019. The main manifestations of this disease are bilateral pneumonia, often accompanied by the development of acute respiratory syndrome and respiratory failure. Patients with diabetes mellitus (DM) are at high risk of infection with the SARS-COV-2 virus, severe illness and death.Maintaining of target glycemic levels is the most important factor in a favorable outcome of COVID-19 in both type 1 and type 2 DM. The choice of antihyperglycemic therapy in a patient with DM in the acute period of COVID-19 depends on the initial therapy, the severity of hyperglycemia, the severity of the viral infection and the patient’s clinical condition.The article presents the recommendations of the board of experts of the Russian Association of Endocrinologists on glycemic control and the choice of antihyperglycemic therapy in patients with type 2 DM and COVID-19, and also on the use of glucocorticosteroids used in the treatment of COVID-19 in patients with type 2 DM. |
| first_indexed | 2024-03-08T15:18:59Z |
| format | Article |
| id | doaj.art-214de775627b4adca10d29072e29433c |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2024-04-24T22:00:52Z |
| publishDate | 2022-03-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-214de775627b4adca10d29072e29433c2024-03-20T11:48:04ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782022-03-01251274910.14341/DM1287310932Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologistsI. I. Dedov0N. G. Mokrysheva1M. V. Shestakova2T. V. Nikonova3A. Yu. Mayorov4G. R. Galstyan5M. Sh. Shamhalova6V. O. Barysheva7A. S. Ametov8M. B. Antsiferov9A. Yu. Babenko10T. P. Bardymova11F. V. Valeeva12A. A. Vachugova13E. N. Grineva14T. Yu. Demidova15T. P. Kiseleva16M. A. Kunicyna17T. N. Markova18A. M. Mkrtumyan19N. A. Petunina20L. A. Ruyatkina21V. V. Saluhov22L. A. Suplotova23E. L. Hadarceva24Yu. Sh. Halimov25Endocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional Education; Endocrinological Dispensary of the Moscow City Health DepartmentAlmazov National Medical Research CentreIrkutsk State Medical Academy of Postgraduate Education — Branch Campus of the Russian Medical Academy of Continuous Professional EducationKazan State Medical UniversityVolgograd Regional Clinical Hospital №1Almazov National Medical Research CentrePirogov Russian National Research Medical UniversityUral State Medical UniversityV.I. Razumovsky Saratov State Medical UniversityA.I. Yevdokimov Moscow State University of Medicine and Dentistry; Moscow City Clinical Hospital №52A.I. Yevdokimov Moscow State University of Medicine and Dentistry; A.S. Loginov Moscow Clinical Scientific CentreI.M. Sechenov First Moscow State Medical University (Sechenov University)Novosibirsk State Medical UniversityS. M. Kirov Military Medical AcademyTyumen State Medical UniversityNorth Caucasus Multi-Profile Medical CenterS. M. Kirov Military Medical AcademyA dangerous viral disease COVID-19, caused by a new RNA coronavirus SARS-COV-2, has been actively spreading in the world since December 2019. The main manifestations of this disease are bilateral pneumonia, often accompanied by the development of acute respiratory syndrome and respiratory failure. Patients with diabetes mellitus (DM) are at high risk of infection with the SARS-COV-2 virus, severe illness and death.Maintaining of target glycemic levels is the most important factor in a favorable outcome of COVID-19 in both type 1 and type 2 DM. The choice of antihyperglycemic therapy in a patient with DM in the acute period of COVID-19 depends on the initial therapy, the severity of hyperglycemia, the severity of the viral infection and the patient’s clinical condition.The article presents the recommendations of the board of experts of the Russian Association of Endocrinologists on glycemic control and the choice of antihyperglycemic therapy in patients with type 2 DM and COVID-19, and also on the use of glucocorticosteroids used in the treatment of COVID-19 in patients with type 2 DM.https://www.dia-endojournals.ru/jour/article/view/12873type 2 diabetes mellituscovid-19antihyperglycemic therapy |
| spellingShingle | I. I. Dedov N. G. Mokrysheva M. V. Shestakova T. V. Nikonova A. Yu. Mayorov G. R. Galstyan M. Sh. Shamhalova V. O. Barysheva A. S. Ametov M. B. Antsiferov A. Yu. Babenko T. P. Bardymova F. V. Valeeva A. A. Vachugova E. N. Grineva T. Yu. Demidova T. P. Kiseleva M. A. Kunicyna T. N. Markova A. M. Mkrtumyan N. A. Petunina L. A. Ruyatkina V. V. Saluhov L. A. Suplotova E. L. Hadarceva Yu. Sh. Halimov Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists Сахарный диабет type 2 diabetes mellitus covid-19 antihyperglycemic therapy |
| title | Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists |
| title_full | Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists |
| title_fullStr | Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists |
| title_full_unstemmed | Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists |
| title_short | Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists |
| title_sort | glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and covid 19 a consensus decision of the board of experts of the russian association of endocrinologists |
| topic | type 2 diabetes mellitus covid-19 antihyperglycemic therapy |
| url | https://www.dia-endojournals.ru/jour/article/view/12873 |
| work_keys_str_mv | AT iidedov glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT ngmokrysheva glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT mvshestakova glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT tvnikonova glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT ayumayorov glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT grgalstyan glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT mshshamhalova glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT vobarysheva glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT asametov glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT mbantsiferov glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT ayubabenko glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT tpbardymova glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT fvvaleeva glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT aavachugova glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT engrineva glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT tyudemidova glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT tpkiseleva glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT makunicyna glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT tnmarkova glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT ammkrtumyan glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT napetunina glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT laruyatkina glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT vvsaluhov glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT lasuplotova glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT elhadarceva glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists AT yushhalimov glycemiacontrolandchoiceofantihyperglycemictherapyinpatientswithtype2diabetesmellitusandcovid19aconsensusdecisionoftheboardofexpertsoftherussianassociationofendocrinologists |